US Patent

US11654142 — Methods for the administration of certain VMAT2 inhibitors

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2038-11-14 · 12y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of administering valbenazine tosylate to patients who are also being given digoxin.

USPTO Abstract

Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,1 1b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate
U-3055 — valbenazine-tosylate

Patent Metadata

Patent number
US11654142
Jurisdiction
US
Classification
Method of Use
Expires
2038-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.